Christopher Brophy v. Jiangbo Pharmaceuticals, Inc. , 781 F.3d 1296 ( 2015 )


Menu:
  •            Case: 14-10213   Date Filed: 03/25/2015   Page: 1 of 24
    [PUBLISH]
    IN THE UNITED STATES COURT OF APPEALS
    FOR THE ELEVENTH CIRCUIT
    ________________________
    No. 14-10213
    ________________________
    D.C. Docket No. 1:11-cv-22556-MGC
    CHRISTOPHER BROPHY,
    TARA LEWIS,
    Plaintiffs - Appellants,
    versus
    JIANGBO PHARMACEUTICALS, INC.,
    JIN LINXIAN,
    ELSA SUNG,
    ZILING SUN,
    CAO WUBO, et al.,
    Defendants - Appellees.
    ________________________
    Appeal from the United States District Court
    for the Southern District of Florida
    ________________________
    (March 25, 2015)
    Before TJOFLAT, JILL PRYOR and FAY, Circuit Judges.
    Case: 14-10213       Date Filed: 03/25/2015      Page: 2 of 24
    JILL PRYOR, Circuit Judge:
    This is an interlocutory appeal from an order granting motions to dismiss by
    two defendants in a securities class action against Jiangbo Pharmaceuticals, Inc.
    (“Jiangbo”), its principal officers, and its audit firm. The district court found that
    plaintiffs Christopher Brophy and Tara Lewis (collectively, the “investors”) failed
    to plead sufficiently their allegations of fraud against defendants Elsa Sung,
    Jiangbo’s former Chief Financial Officer (“CFO”), and Frazer LLP (“Frazer”),
    Jiangbo’s external auditor. Applying the heightened pleading standard imposed by
    the Private Securities Litigation Reform Act (“PSLRA”), 15 U.S.C. § 78u–4, we
    affirm.
    I.     BACKGROUND
    A. Jiangbo’s troubled tenure on NASDAQ 1
    Jiangbo came into existence as a U.S. corporation in 2007 when its Chinese
    operational arm, Laiyang Jiangbo, executed a reverse merger with a Florida shell
    company. 2 The day-to-day operations of Jiangbo’s pharmaceutical business
    remained in China. Jiangbo hired Elsa Sung, a Florida resident, to be its CFO in
    October of 2007. She remained in her position for several years, throughout most
    1
    We draw the facts below from the complaint and construe them in the light most favorable to
    the plaintiffs, as we must on review of a motion pursuant to Federal Rule of Civil Procedure
    12(b)(6). See infra Part II.
    2
    The name of the shell company was Genesis Technology Group, Inc. Jiangbo acquired its
    current name in 2009.
    2
    Case: 14-10213       Date Filed: 03/25/2015       Page: 3 of 24
    of the class period during which the investors allege that Jiangbo engaged in fraud,
    until she resigned on March 31, 2011. On February 25, 2008, Jiangbo first
    retained one of Frazer’s predecessor entities, Moore Stephens, as its principal
    accountant. The investors claim that a number of other Chinese corporations
    created through reverse mergers eventually also retained Moore Stephens’s
    successor entity, Frazer Frost LLP, as their external auditor. Frazer Frost LLP
    remained Jiangbo’s auditor during most of the class period, until approximately the
    end of March 2011, when Jiangbo replaced it with another firm. Frazer came into
    being as one of two successor entities when Frazer Frost LLP split on May 1,
    2011. 3
    Jiangbo’s tenure as a public company was short and fraught with suspicion
    of misconduct. Shares began trading on NASDAQ on June 8, 2010 and traded on
    that exchange for just under a year. 4 Only six months after trading began, in
    December 2010, the Securities and Exchange Commission (“SEC”) initiated an
    informal, non-public investigation and requested certain documents from Jiangbo.
    By February 2011, Jiangbo’s internal Audit Committee had launched its own non-
    public investigation into the SEC’s areas of concern and retained Cadwalader,
    Wickersham & Taft LLP (“Cadwalader”) and Ernst & Young (“E&Y”) to assist in
    3
    The other entity produced by the split was Frost PLLC. The investors allege that both are liable
    for fraud, but they disclaim any appeal as to Frost PLLC.
    4
    The class period is the period during which Jiangbo shares traded on NASDAQ.
    3
    Case: 14-10213      Date Filed: 03/25/2015     Page: 4 of 24
    that investigation. The company’s fortunes unraveled quickly soon thereafter. In
    or around March 2011, Ms. Sung and Frazer withdrew from their respective roles,
    and the SEC formalized its investigation, which remained non-public.
    Jiangbo made two significant disclosures in late May 2011 that marked the
    culmination of its decline: it publicly acknowledged the formal SEC investigation
    for the first time and reported that the company had defaulted on a relatively small
    principal payment toward debt from its initial financing. Trading ended days later
    on May 31, 2011, by which time the share price had fallen from a class-period high
    of $10.49 per share to $3.08. By November 2011, after Jiangbo had moved to
    another exchange, its shares were trading for just $0.14.
    B. The nature of the alleged fraud
    As required by securities law governing publicly traded companies, Jiangbo
    submitted filings to the SEC that disclosed the company’s finances and other
    material information. 5 The investors’ consolidated amended complaint (the
    “complaint”) alleges, inter alia, that Ms. Sung and Frazer misrepresented the
    company’s cash balances and failed to disclose a material related-party transaction
    in statements within or appurtenant to those filings, in violation of Section 10(b) of
    the Securities Exchange Act, 15 U.S.C. § 78j(b), and SEC Rule 10b–5, 17 C.F.R.
    5
    These filings included Form 10-Ks, Form 10-Qs, and Form 8-Ks.
    4
    Case: 14-10213        Date Filed: 03/25/2015       Page: 5 of 24
    § 240.10b–5. 6 The alleged related-party transaction involved a $31 million
    transfer to Shandong Hilead Biotechnology Co., Ltd. (“Hilead”), a company
    controlled by Jiangbo chairman Cao Wubo, who is a defendant in the underlying
    action.
    1. Cash balances
    During the class period, Jiangbo consistently reported in its filings with the
    SEC that its cash balances were near or above $100 million. As CFO, Ms. Sung
    certified to the SEC that Jiangbo had sufficient internal controls and procedures to
    ensure that the filings were accurate and that no material information was missing. 7
    In addition to signing these certifications within Jiangbo’s filings, Ms. Sung
    participated in multiple conference calls with shareholders in which she reiterated
    cash balances from the filings. During these calls, Ms. Sung emphasized to
    shareholders that the company’s growth and cash position were “strong.” Doc. 43
    at ¶¶ 150, 158, 170.
    The investors allege that Jiangbo’s cash balances were overstated in the
    SEC filings and, consequently, that Ms. Sung’s formal certifications and verbal
    confirmations of the figures were material misrepresentations. The complaint lists
    6
    The complaint also alleges that Jiangbo overstated its accounts receivable and failed to disclose
    the SEC investigation in filings that followed, but the investors do not assert these claims on
    appeal.
    7
    After Ms. Sung stepped down, she ceased to certify filings or make public statements about
    Jiangbo’s financial position on behalf of the company. Accordingly, the investors assert no
    claims against Ms. Sung based on misrepresentations or omissions occurring after her
    resignation became effective on March 31, 2011.
    5
    Case: 14-10213       Date Filed: 03/25/2015      Page: 6 of 24
    irregularities in Jiangbo’s management of its finances that support an inference that
    its cash balances were actually much lower. First, Jiangbo defaulted in early 2011
    on a relatively small principal payment—$3.5 million—that it owed on debt from
    its initial financing years earlier. Second, Jiangbo failed to make timely payments
    to Cadwalader and E&Y for their assistance in the internal investigation, and when
    the company ultimately made a partial payment of only RMB 2.2 million,8 the
    funds appeared to have come from the personal account of a Jiangbo employee.
    The investors reason that if Jiangbo’s cash balances really had been in excess of
    $100 million for most of the class period, Jiangbo would not have had trouble
    meeting such minimal obligations.
    2. Hilead transaction
    The investors additionally allege that Jiangbo was involved in a material
    related-party transaction with Hilead that none of Jiangbo’s principal officers,
    including Ms. Sung, properly disclosed in filings or public statements. The
    investors first learned that this transaction might have occurred from the
    resignation letter, dated June 6, 2011, of two of Jiangbo’s independent board
    members who sat on the Audit Committee (the “resignation letter”). The
    resignation letter noted that the Audit Committee had issued unsatisfied requests
    for bank slips showing receipt of the same amount—RMB 200 million, or roughly
    8
    Using the conversion rate contained in the complaint, the dollar equivalent would have been
    approximately $341,000.
    6
    Case: 14-10213    Date Filed: 03/25/2015    Page: 7 of 24
    $31 million—from both Jiangbo and Hilead. The letter further stated that the
    Audit Committee was awaiting an “Auditor’s Verification Report on the capital
    injection in relation to the RMB 200 million capital of Hilead . . . .” Doc. 43-1 at
    20-21. Given Mr. Cao’s control of Hilead and the size of the transaction relative to
    Jiangbo’s stated cash balances, the investors allege that any such transaction was
    necessarily “material” and should have been disclosed. Thus, the investors claim
    that Ms. Sung’s certification of filings and statements to shareholders made
    material omissions under the meaning of 
    17 C.F.R. § 240
    .10b-5 insofar as they did
    not reference the Hilead transaction.
    3. Frazer’s alleged role in the fraud
    The investors allege that Frazer is liable for the same two material
    misrepresentations or omissions as Ms. Sung, citing a single unqualified audit
    report that Frazer issued regarding the fiscal year ending in June 2010, which
    Jiangbo included in its September 2010 filings with the SEC. The investors argue
    that Frazer’s confirmation of the integrity of Jiangbo’s reporting amounts to the
    same material misrepresentations and omissions within Jiangbo’s filings
    themselves.
    C. Proceedings below
    The underlying action is a consolidation of two actions that were filed
    against Jiangbo in the months after its collapse. The investors were appointed lead
    7
    Case: 14-10213     Date Filed: 03/25/2015    Page: 8 of 24
    plaintiffs of this new action on November 1, 2011 and filed the consolidated
    amended complaint on November 16, 2011. The complaint laid out two types of
    claims: violations of Section 10(b), the principal fraud provision of the Securities
    Exchange Act, and corollary claims under Section 20(a), which attaches liability to
    individual persons who control corporations responsible for predicate violations of
    the Act. See 15 U.S.C. §§ 78j, 78t. The investors sought to recover the losses in
    the value of their holdings that they allege resulted from earlier, fraudulently
    inflated stock prices and the market’s subsequent recognition of that fraud.
    Ms. Sung and Frazer moved to dismiss, asserting that the complaint does not
    sufficiently plead either scienter or the existence of material misrepresentations or
    omissions, both of which are required to establish a violation of Section 10(b).
    The district court granted the motions and dismissed the complaint as to Ms. Sung
    and Frazer, concluding that the complaint fails to state with particularity facts
    giving rise to a strong inference that Ms. Sung or Frazer acted with scienter, even
    though the complaint properly pleads allegations that Jiangbo overstated cash
    balances. This appeal followed.
    II.    ANALYSIS
    “We review de novo the district court’s dismissal of a case under [Federal
    Rule of Civil Procedure] 12(b)(6), ‘accepting the allegations in the complaint as
    true and construing them in the light most favorable to the plaintiff.’” Piedmont
    8
    Case: 14-10213     Date Filed: 03/25/2015    Page: 9 of 24
    Office Realty Trust, Inc. v. XL Speciality Ins. Co., 
    769 F.3d 1291
    , 1293 (11th Cir.
    2014) (quoting Hill v. White, 
    321 F.3d 1334
    , 1335 (11th Cir. 2003)). To plead
    securities fraud in violation of Section 10(b), the investors must sufficiently allege
    the following elements: “(1) a material misrepresentation or omission; (2) made
    with scienter; (3) a connection with the purchase or sale of a security; (4) reliance
    on the misstatement or omission; (5) economic loss; and (6) a causal connection
    between the material misrepresentation or omission and the loss . . . .” Mizzaro v.
    Home Depot, Inc., 
    544 F.3d 1230
    , 1236-37 (11th Cir. 2008). Our task is to
    evaluate the district court’s conclusions with respect to the first two elements.
    Even assuming arguendo that the investors have sufficiently pled their allegations
    of misrepresentations and omissions, we find that significant ambiguities in those
    allegations make an inference of scienter more difficult to draw. For that reason,
    we agree with the district court that the complaint fails to plead that either Ms.
    Sung or Frazer acted with scienter.
    Under the PSLRA, a plaintiff cannot “plead the requisite scienter element
    generally . . . .” 
    Id. at 1238
    . “In this Circuit, § 10(b) and Rule 10b–5 require a
    showing of either an ‘intent to deceive, manipulate, or defraud,’ or ‘severe
    recklessness.’” Thompson v. RelationServe Media, Inc., 
    610 F.3d 628
    , 634 (11th
    Cir. 2010) (quoting Mizzaro, 
    544 F.3d at 1238
    ). “[T]he complaint shall, with
    respect to each act or omission alleged to violate [the Securities Exchange Act],
    9
    Case: 14-10213       Date Filed: 03/25/2015       Page: 10 of 24
    state with particularity facts giving rise to a strong inference that the defendant
    acted with the required state of mind.” 15 U.S.C. § 78u-4(b)(2)(A). Accordingly,
    “[a] complaint will survive [a motion to dismiss] only if a reasonable person would
    deem the inference of scienter cogent and at least as compelling as any opposing
    inference one could draw from the facts alleged.” Tellabs, Inc. v. Makor Issues &
    Rights, Ltd., 
    551 U.S. 308
    , 324 (2007). Although we draw any reasonable
    inferences available on the face of the complaint in the investors’ favor, we also
    must look to “plausible, nonculpable explanations for the defendant’s conduct” in
    evaluating an inference of scienter. 
    Id.
     In determining the relative merit of
    opposing inferences, we “must consider the complaint in its entirety . . . .” 
    Id. at 322
    .
    A. Ms. Sung
    We turn first to the investors’ allegation that Ms. Sung confirmed false
    reports of Jiangbo’s cash balances in SEC filings and shareholder conference
    calls.9 On appeal, the investors assert the following bases for an inference that Ms.
    Sung acted with scienter with respect to overstated cash balances: the magnitude
    of the overstatements; the internal control problems at Jiangbo that were revealed
    in the resignation letter; the existence of an SEC investigation; Ms. Sung’s position
    9
    We need only discuss whether there is a strong inference that Ms. Sung acted with scienter
    when she overstated Jiangbo’s cash balances. In Part II.A.3, infra, we show that the investors’
    failure to plead the timing of the Hilead transaction precludes any inference of scienter that
    might have arisen from the transaction.
    10
    Case: 14-10213        Date Filed: 03/25/2015       Page: 11 of 24
    as CFO; Ms. Sung’s alleged involvement in obstructing the Audit Committee’s
    internal investigation; and Ms. Sung’s resignation effective March 31, 2011.10
    Ms. Sung argues that the opposing inference, that she acted without scienter,
    is more compelling in the light of several factors: the absence of particularized
    allegations that Ms. Sung actually knew about or was on notice of any alleged
    deficiencies in Jiangbo’s reporting; ambiguities and other weaknesses in the
    investors’ allegations of incorrect cash balances; Ms. Sung’s residency in Florida,
    on a different continent from Jiangbo’s day-to-day operations; Ms. Sung’s
    assertion that she resigned for family reasons and her decision to continue working
    with Jiangbo as a part-time consultant after her resignation; and the complaint’s
    failure to allege that Ms. Sung sold any shares during the class period or otherwise
    profited from the alleged fraud.
    From the outset, we note that the investors allege no particularized facts that
    directly show Ms. Sung intended to deceive shareholders or knew about or was
    severely reckless with respect to deficiencies in reporting. See Thompson, 
    610 F.3d at 634
    . The investors offer no allegations describing Ms. Sung’s day-to-day
    practices as CFO or identifying any specific misconduct apart from confirming
    incorrect cash balances within filings and on conference calls. Instead, the
    10
    The investors also assert as a basis for an inference of scienter the fact that Ms. Sung
    misrepresented her status as a Certified Public Accountant (“CPA”) in SEC filings. We agree
    with the district court that any discrepancy in Ms. Sung’s representation that she was a licensed
    CPA is immaterial.
    11
    Case: 14-10213      Date Filed: 03/25/2015    Page: 12 of 24
    investors’ theory is essentially that Ms. Sung must have been aware of the
    misrepresentations in Jiangbo’s filings, given (1) her role as CFO in a company
    plagued with serious fraud and (2) her suspicious actions during Jiangbo’s rapid
    decline. We begin our analysis by assessing whether the allegations regarding the
    scope of the fraud, in the light of Ms. Sung’s position as CFO, can support a strong
    inference of scienter by themselves. Keeping in mind the relative strength of those
    allegations, we then turn to whether the allegations that Ms. Sung resigned in the
    midst of Jiangbo’s decline and that she participated in the obstruction of the
    internal investigation are sufficient to establish a strong inference of scienter.
    1. Allegations regarding the scope of the fraud
    The investors assert that the alleged fraud was so significant and obvious
    that Ms. Sung must have known about it, or else she was severely reckless in
    avoiding knowledge of the fraud. First, the investors claim that the disparity
    between Jiangbo’s actual and reported cash balances must have been extreme—in
    the tens or hundreds of millions of dollars—so that it would have been difficult or
    impossible for Ms. Sung not to have known about it in her capacity as CFO. To
    support this inference of scienter, the investors continue to rely heavily on their
    allegations supporting the underlying inference that Jiangbo’s accounts were
    overstated. Those allegations include: the company’s failure to make payments on
    debts in amounts that were a small fraction of the stated cash on hand, irregularities
    12
    Case: 14-10213     Date Filed: 03/25/2015    Page: 13 of 24
    in payments to auditors and lawyers in similarly small amounts, the overt concern
    of the independent board members that cash balances were stated inaccurately, and
    the lack of cooperation from Jiangbo’s top management during the internal
    investigation.
    Second, the investors allege that a number of red flags should have put Ms.
    Sung on notice of the fraud. The investors argue that the existence of the SEC
    investigation supports an inference of scienter in two ways: the investigation
    should have put Ms. Sung on notice that Jiangbo’s financial reporting required
    more of her own scrutiny, and the fact of the investigation itself suggests that the
    fraud was significant in its scope. Further, the investors cite the following
    deficiencies in Jiangbo’s management of its financial reporting during the class
    period that, according to the investors, should have prompted Ms. Sung to look for
    and discover the fraud: “(1) weaknesses among the accounting and finance
    personnel, (2) dysfunctional internal controls, and (3) inadequate segregation of
    duties in the financial reporting function.” Doc. 43 at ¶ 196.
    The investors rely on the two arguments above to establish successive
    inferences: that material misrepresentations occurred and that Ms. Sung acted with
    scienter in making those representations. While the totality of the allegations may
    well be sufficient to support an inference that Jiangbo materially misrepresented its
    cash balances, we might still harbor uncertainty about that underlying inference
    13
    Case: 14-10213     Date Filed: 03/25/2015     Page: 14 of 24
    when assessing the strength of an inference of scienter. Any “omissions and
    ambiguities count against inferring scienter, . . . [and] the court’s job is not to
    scrutinize each allegation in isolation but to assess all the allegations holistically.”
    Tellabs, 
    551 U.S. at 326
    . In a similar vein, this Court has recognized that an
    inference of scienter is diluted to the extent it is drawn from multiple predicate
    inferences that are each based on the same allegations. See Garfield v. NDC
    Health Corp., 
    466 F.3d 1255
    , 1265 (11th Cir. 2006).
    Regarding the investors’ first argument, we agree with the district court and
    Ms. Sung that several omissions and ambiguities weaken any inference of scienter
    to be drawn from the magnitude of alleged overstatements or any red flags. First,
    although the investors emphasize the magnitude by which they allege Jiangbo
    overstated cash balances, they fail to allege any particular amount or even a range;
    they merely assert in their briefs that the actual balances were “extremely limited[]
    and nowhere near” the full cash balances reported. Appellants’ Br. at 38. Without
    more specifics, the investors cannot persuasively allude to the magnitude of the
    fraud as a basis for a strong inference that Ms. Sung must have known of the errors
    as CFO. See Mizzaro, 
    544 F.3d at 1251
     (“[W]e have no reliable way of estimating
    [the fraud’s] total amount, let alone inferring from the dollar amount the
    knowledge of senior management.”).
    14
    Case: 14-10213     Date Filed: 03/25/2015   Page: 15 of 24
    As regards the investors’ second argument, we are not persuaded that the red
    flags the investors identify would have made Jiangbo’s fraud obvious to Ms. Sung,
    even if we also assume that some overstatement of cash balances occurred, because
    the complaint provides no explanation as to how these red flags should have
    alerted her to the fraud. Regarding the SEC investigation, the district court
    correctly noted that “the [complaint] does not contain any allegations about what
    [Ms.] Sung knew about the scope of the investigation[].” In re Jiangbo Pharm.,
    Inc., Sec. Litig., 
    884 F. Supp. 2d 1243
    , 1263 (S.D. Fla. 2012). The “mere existence
    of an SEC investigation” likewise does not equip a reviewing court to explain
    which inferences might be available beyond a general suspicion of wrongdoing. In
    re Hutchinson Tech., Inc. Sec. Litig., 
    536 F.3d 952
    , 962 (8th Cir. 2008). The
    investors’ allegations of internal control problems suffer from the same limitation.
    With no explanation as to how these vaguely defined problems would have
    affected financial reporting or how Ms. Sung would have known about them, we
    cannot rely on them to add much weight to an inference of scienter.
    The investors would have us rely solely on Ms. Sung’s position as CFO to
    overlook these omissions and ambiguities in the complaint. They cite cases in
    which courts recognized a strong inference of scienter based in part on a senior
    financial executive’s oversight of the processes that produce the company’s
    financial statements. However, those cases involve particularized allegations that
    15
    Case: 14-10213      Date Filed: 03/25/2015    Page: 16 of 24
    the executives knew or were severely reckless in disregarding how those processes
    were distorted by fraud, and so they do not inform our discussion. See Institutional
    Investors Grp. v. Avaya, Inc., 
    564 F.3d 242
    , 270 (3d Cir. 2009) (finding a strong
    inference that a CFO was at least reckless in endorsing flawed financial projections
    because of repeated, focused inquiries from analysts that correctly suggested why
    the projections were implausible); Freudenberg v. E*Trade Fin. Corp., 
    712 F. Supp. 2d 171
    , 198-99 (S.D.N.Y. 2010) (finding a strong inference that a CFO acted
    with scienter on the basis of allegations that he personally reviewed erroneous loan
    valuations, communicated often with other executives and subordinates, and gave
    “reassurances” to investors regarding the key issues in the case); In re Friedman’s,
    Inc. Sec. Litig., 
    385 F. Supp. 2d 1345
    , 1363 (N.D. Ga. 2005) (finding scienter
    properly pled where the company’s controller was alleged to have reviewed
    incriminating documents personally and made specific choices in pursuit of an
    illegal scheme).
    Without more particularized allegations, the investors’ claim that Jiangbo’s
    fraud was too large for Ms. Sung not to have noticed is unpersuasive. We now
    consider whether the investors’ allegations of Ms. Sung’s suspicious behavior can
    fill the gaps in their allegations regarding the scope of the fraud.
    16
    Case: 14-10213     Date Filed: 03/25/2015    Page: 17 of 24
    2. Ms. Sung’s resignation and alleged obstruction of the Audit Committee
    The investors argue that two actions Ms. Sung took during Jiangbo’s decline
    are persuasive, if circumstantial, proof of her knowledge of the fraud: her
    resignation as CFO and her alleged obstruction of the Audit Committee’s internal
    investigation.
    Various courts have recognized that an executive officer’s resignation can
    strengthen an inference of scienter when it occurs around the same time as an
    investigation. See, e.g., Fouad v. Isilon Sys., Inc., No. C07–1764, 
    2008 WL 5412397
    , at *11 (W.D. Wash. Dec. 29, 2008). The investors do not offer any
    reason why Ms. Sung’s resignation would be incriminating other than for its
    proximity to internal and external investigations, and so they rely on the general
    intuition that an officer resigning amid allegations of fraud seeks to disassociate
    herself from any appearance of wrongdoing. Ms. Sung argued in her motion to
    dismiss that her “family reasons” for resigning and her continued work for Jiangbo
    as a consultant after her resignation belie any suggestion that she wanted to
    disassociate herself from fraud. Doc. 51 at 29. We find this explanation more
    compelling than the investors’ desired inference. Though we do not reflexively
    credit Ms. Sung’s assertion that she had family reasons for resigning, the fact that
    she continued to work for the company on a part-time basis equally supports a
    17
    Case: 14-10213     Date Filed: 03/25/2015   Page: 18 of 24
    nonculpable explanation. Her resignation adds weight to an overall inference of
    scienter, but not a substantial amount of weight.
    Regarding the investors’ contention that Ms. Sung demonstrated her
    knowledge of the fraud by assisting Mr. Cao in obstructing the Audit Committee’s
    internal investigation, we note that obstruction of an investigation supports an
    inference of scienter, particularly where defendants affirmatively make efforts to
    conceal fraud. See, e.g., Katz v. Image Innovations Holdings, Inc., 
    542 F. Supp. 2d 269
    , 274 (S.D.N.Y. 2008). The investors claim that Ms. Sung refused to turn over
    materials requested by the Audit Committee because she was waiting for Mr.
    Cao’s authorization. While the resignation letter makes clear that she did not grant
    the Audit Committee the access it requested, the letter also explains that she
    personally prepared the materials for review and preliminarily agreed to turn them
    over pending the company’s approval. Doc. 43-1 at 13. Even if she neglected a
    prevailing duty to provide her materials to the committee regardless of the
    chairman’s wishes, we do not think these facts add much weight to an inference of
    scienter, given that she apparently was willing to turn the materials over. The
    investors do not allege that she was otherwise unwilling to cooperate or that she
    took any steps to conceal documents that might reveal fraud.
    18
    Case: 14-10213     Date Filed: 03/25/2015    Page: 19 of 24
    3. Timing of the Hilead transaction
    We agree with the district court that the lack of information in the complaint
    concerning the timing of the Hilead transaction is fatal to the allegation that it was
    a material omission in Jiangbo’s SEC filings. “A defendant’s omission to state a
    material fact is proscribed only when the defendant has a duty to disclose.”
    Ziemba v. Cascade Int’l, Inc., 
    256 F.3d 1194
    , 1206 (11th Cir. 2001) (alteration and
    internal quotation marks omitted). The investors contend that Ms. Sung had a
    general duty “to promptly disseminate accurate and truthful information” that was
    material to the market price of the stock. Doc. 43 at ¶ 80. Similarly, they contend
    that Frazer did not exercise “due professional care” in ensuring the accuracy of its
    report. 
    Id. at ¶¶ 195-96
    . Absent any allegation of when the transaction took place,
    however, we cannot conclude that Ms. Sung or Frazer violated a duty to disclose
    the transaction. Furthermore, even if the lack of factual allegations regarding
    timing did not preclude the investors from identifying a duty to disclose with
    respect to any given filing, the complaint’s barebones information about the
    alleged transaction would be far from sufficient to tie Ms. Sung to the transaction
    in any meaningful way. Thus, we do not rely upon the Hilead transaction in
    conducting our scienter analysis.
    19
    Case: 14-10213     Date Filed: 03/25/2015    Page: 20 of 24
    4. Scienter analysis
    To complete our scienter analysis as to Ms. Sung, we must consider her
    additional arguments that weigh against an inference of scienter. See Tellabs, 
    551 U.S. at 324
    . First, as a resident of Florida, she was not physically present to
    observe Jiangbo’s day-to-day operations in China. Second, there is no allegation
    that she sold Jiangbo stock during the class period or otherwise profited from the
    alleged fraud beyond receiving a salary. In the light of these observations and
    those articulated above, we conclude that the complaint does not give rise to a
    sufficiently strong inference of scienter as to Ms. Sung. We acknowledge that Ms.
    Sung’s resignation and her failure to cooperate fully with the Audit Committee are
    grounds for some suspicion, but the investors are hard pressed to explain how this
    suspicion is more particularized than the general impression that fraud was taking
    place at Jiangbo in some unknown fashion. We also acknowledge that if the
    investors’ allegations of overstated cash balances are true, then the investors would
    have a strong case that Ms. Sung was negligent not to know about these
    discrepancies. The initiation of two investigations suggests that Ms. Sung may
    have failed to fulfill basic duties to investors in her capacity as CFO. However,
    upon drawing all reasonable inferences in the investors’ favor, we do not think the
    complaint establishes that she must have known about discrepancies in reporting or
    that she was severely reckless in not knowing about them. The seriousness of
    20
    Case: 14-10213     Date Filed: 03/25/2015    Page: 21 of 24
    Jiangbo’s errors and Ms. Sung’s proximity to those errors at most imply
    negligence, which is not enough to establish scienter. See Bryant v. Avado Brands,
    Inc., 
    187 F.3d 1271
    , 1281-82 (11th Cir. 1999).
    B. Frazer
    The only basis for the investors’ claim against Frazer is one unqualified
    audit opinion dated September 28, 2010 and included in Jiangbo’s report on fiscal
    year 2010, ending June 30, 2010. That opinion found Jiangbo to be in conformity
    with proper accounting principles for the years 2008, 2009, and 2010. The
    investors argue that Frazer should have disclosed any overstatements of cash
    balances and material related-party transactions in this report. The arguments in
    support of an inference of scienter on Frazer’s part are similar to those levied
    against Ms. Sung: (1) as auditor, Frazer would have had direct knowledge of cash
    balances and internal control problems; (2) the SEC launched a formal
    investigation; and (3) Frazer withdrew from consideration for reappointment
    around the same time as Ms. Sung resigned and the SEC investigation began. We
    note, however, that the timing of Frazer’s opinion precludes some of the inferences
    that the investors seek to draw against Ms. Sung because many of the alleged red
    flags in this case appeared later in 2010 and then in 2011, after the opinion was
    issued.
    21
    Case: 14-10213     Date Filed: 03/25/2015    Page: 22 of 24
    The district court employed the following standard for evaluating an
    inference of scienter as to an external auditor:
    “[Plaintiffs] must prove that the accounting practices were so deficient
    that the audit amounted to no audit at all, or an egregious refusal to
    see the obvious, or to investigate the doubtful, or that the accounting
    judgments which were made were such that no reasonable accountant
    would have made the same decisions if confronted with the same
    facts.”
    In re Worlds of Wonder Secs. Litig., 
    35 F.3d 1407
    , 1426 (9th Cir. 1994) (quoting
    SEC v. Price Waterhouse, 
    797 F. Supp. 1217
    , 1240 (S.D.N.Y. 1992)). We think
    this standard satisfactorily clarifies the plaintiff’s obligation in such cases, and so
    we also employ it. Of course, the complaint must give rise to a strong inference
    that the auditor is responsible for such ineptitude or misconduct.
    If the inference of scienter against Ms. Sung is tenuous, then the
    corresponding inference against Frazer is even more attenuated. As an external
    auditor, Frazer was a step more removed than Ms. Sung from any alleged
    indicators of the fraud. See Reiger v. PricewaterhouseCoopers LLP, 
    117 F. Supp. 2d 1003
    , 1007-08 (S.D. Cal. 2000) (“[B]ecause an independent accountant often
    depends on its client to provide the information base for the audit, it is almost
    always more difficult to establish scienter on the part of the accountant than on the
    part of its client.”). Moreover, the investors’ allegations of Frazer’s suspicious
    behavior are unavailing. Although the investors assert that Frazer resigned, more
    accurately, Frazer did not stand for reappointment for the following year. The
    22
    Case: 14-10213   Date Filed: 03/25/2015   Page: 23 of 24
    separation in time between Frazer’s unqualified opinion and its withdrawal from
    consideration for reappointment further mitigates any inference of scienter that
    might arise from the firm’s withdrawal.
    Ultimately, the investors’ allegations against Frazer suffer from the same
    overarching deficiency as those against Ms. Sung: they fail to articulate a theory
    of the fraud with any particularity. The complaint does not set out in what ways
    Frazer’s audit was deficient, there is no allegation that Frazer had extensive
    involvement with the company beyond what was required to conduct a single
    audit, and there is no connection between the fact of an SEC investigation and
    Frazer’s state of mind that a reviewing court may reasonably draw on the face of
    the complaint. The complaint might make a strong case for negligence—but again,
    negligence is not enough to establish a strong inference of scienter. See Bryant,
    
    187 F.3d at 1281-82
    . The investors fail to satisfy the heightened pleading standard
    as to Frazer.
    III.   CONCLUSION
    The investors fail to allege a theory of fraud that is specific enough in its
    scope or its connection to Ms. Sung or Frazer to support a strong inference of
    scienter. Therefore, we need not address the other elements of a Section 10(b)
    violation or the corollary Section 20(a) claim applicable only to Ms. Sung.
    Although the allegations against Ms. Sung and Frazer might survive motions to
    23
    Case: 14-10213   Date Filed: 03/25/2015   Page: 24 of 24
    dismiss under a less burdensome pleading standard, the PSLRA imposes a high
    bar.
    AFFIRMED.
    24